US3812147A - Acylxylidide local anaesthetics - Google Patents

Acylxylidide local anaesthetics Download PDF

Info

Publication number
US3812147A
US3812147A US00164022A US16402271A US3812147A US 3812147 A US3812147 A US 3812147A US 00164022 A US00164022 A US 00164022A US 16402271 A US16402271 A US 16402271A US 3812147 A US3812147 A US 3812147A
Authority
US
United States
Prior art keywords
ether
mole
amide
butyroxylidide
filtered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00164022A
Inventor
H Adams
G Kronberg
B Takman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astra USA Inc
Original Assignee
Astra Pharmaceutical Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharmaceutical Products Inc filed Critical Astra Pharmaceutical Products Inc
Priority to US00164022A priority Critical patent/US3812147A/en
Priority to SE7115656A priority patent/SE393374B/en
Priority to BE776656A priority patent/BE776656A/en
Priority to SU1726195A priority patent/SU419023A3/en
Priority to HUAA690A priority patent/HU163373B/hu
Priority to DK619771AA priority patent/DK139814B/en
Priority to NO4669/71A priority patent/NO135934C/no
Priority to DE2162744A priority patent/DE2162744C3/en
Priority to IT54845/71A priority patent/IT1066334B/en
Priority to IE1609/71A priority patent/IE35909B1/en
Priority to AU37099/71A priority patent/AU468489B2/en
Priority to AT1089671A priority patent/AT319205B/en
Priority to DD159785A priority patent/DD99779A5/xx
Priority to CH1862971A priority patent/CH573396A5/en
Priority to AR239721A priority patent/AR193840A1/en
Priority to BR8466/71A priority patent/BR7108466D0/en
Priority to GB5937771A priority patent/GB1369259A/en
Priority to FR7145983A priority patent/FR2118985B1/fr
Priority to PL1971152331A priority patent/PL83097B1/pl
Priority to CA130,662A priority patent/CA943966A/en
Priority to ES398210A priority patent/ES398210A1/en
Priority to JP10453571A priority patent/JPS5644063B1/ja
Priority to NLAANVRAGE7117644,A priority patent/NL172149C/en
Priority to FI3658/71A priority patent/FI55027C/en
Priority to US447680A priority patent/US3862321A/en
Priority to ES425626A priority patent/ES425626A1/en
Application granted granted Critical
Publication of US3812147A publication Critical patent/US3812147A/en
Priority to NL8204126A priority patent/NL8204126A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/38Acyl halides
    • C07C53/46Acyl halides containing halogen outside the carbonyl halide group
    • C07C53/50Acyl halides containing halogen outside the carbonyl halide group of acids containing three or more carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups

Definitions

  • the present invention relates to 2-alkyl-2-alkylamino- 2',6-acetoxylidide local anaesthetic compounds.
  • acylxylidide local anaesthetic compounds which are commercially available are N-n-butylpipecolyl- 2,6- xylidide or bupivacaine sold under the trademark Marcaine having the structural formula O C H:
  • the principal object of the present invention to provide compounds which generally have the combined properties of long lasting local anaesthetic effect or high local anaesthetic activity, a satisfactory low level of tissue irritation and a satisfactory low acute toxicity.
  • the compounds of the present invention are the 2- alkyl-2-alkylamino-2',6' acetoxylidide local anaesthetic compounds having the structural formula wherein R is ethyl, propyl or butyl; R and R may be the same or diiferent alkyl radicals and are methyl, ethyl,
  • Representative compounds include the following: 2- diethylamino-Z,6'-n-butyroxylidide, which can be alternatively named 2-ethyl-2-diethylamino-2',6'-acetoxylidide,
  • R R and R are as stated above and X is a bromine or a chlorine atom. More detailed and other procedures of preparation are given in the representative examples hereinafter.
  • racemic compounds may be resolved into their dand l-optical isomers by treatment with land d-tartaric acid.
  • the compounds of the invention are useful as local anaesthetics in the conventional manner and employing conventional dosages thereof.
  • These bases may be conventionally used in the form of solutions of their pharmaceutically acceptable salts, e.g., the hydrochlorides, tartrates and citrates.
  • EXAMPLE 1 This example illustrates the preparation of Z-diethylamino-2', -n-butyroxylidide or or. (diethylamino) nbutyro-2,6-xylidide.
  • a product sufiiciently pure for the following reaction was obtained by omitting the vacuum distillation and allowing a stream of dry argon (or nitrogen) to pass through the u-bromo-n-butyryl chloride at 80100 C. for 1.5-2 hours after the main bulk of thionyl chloride had been distilled 01f.
  • EXAMPLE 2 This example illustrates the preparation of Z-(N-ethyln-propylamino) 2',6' butyroxylidide or a-(N-ethyl-n propylamino)-n-butyro-2,6-xylidide.
  • the uncrystallized product contains some of the bromo compound but was sufliciently pure for the following step.
  • the solid fraction I and the acid solution II were corn-t bined and based out with 7 M NaOH and the freed base was extracted into ether. After drying over anhydrous sodium sulfate the ether extract was filtered and evaporated yielding 93 g. of a partly solidifying marooncolored residue.
  • the ether extracts yielded 79.2 g. of a base that contained mainly the desired compound and which was sufficiently pure for the next step.
  • the hydrochloride hydrate was prepared from the base with ethereal hydrogen chloride and addition of water. Recrystallized from ethanol/ether it melted at 199-1995 C. Calculated for the base (C H N O): C, 72.5; H, 9.74; N, 11.3. Found: C, 72.5; H, 9.81; N, 11.2.
  • the bases were liberated from the two tartrates with sodium hydroxide in water.
  • the bases from (I) and (II) had specific rotation of +34.1 and -32.8, respectively.
  • the rotation of their hydrochlorides were +6.2 and -6.2, respectively, after recrystallization from abs. ethanol-ether.
  • Their melting points were identical, 184- 185 C.
  • racemic compounds of Examples 1 and 4-8 can be resolved into the dand l-optical isomers thereof by a procedure similar to the one of Example 3.
  • EXAMPLE 4 This example illustrates the preparation of Z-diethylamino-2',6-n-valeroxylidide.
  • 2-diethylamino-Z,6'-n-valeroxylidide A mixture of 2-bromo-2,6'-n-valeroxylidide (0.176 mole), diethylamine (0.528 mole), and benzene (125 ml.) was placed in a pressure vessel and heated to C. for 35 hours. After cooling, the dark brown content was filtered and the solid (23.2 g. of diethylammonium bromide) washed carefully with benzene.
  • the filtrate was extracted with 4 N hydrochloric acid (3 X 50 ml.), the acid extract washed with ether (3X 50 ml.), and based out with 7 N sodium hydroxide under cooling and stirring and in the presence of ether (100 ml.). After two further extractions with ether (2X 50 ml.) the combined ether extracts were dried (Na SO and the ether evaporated leaving 16.5 g. of residue.
  • the hydrochloride was prepared from the residue by dissolving it in ether and adding ethereal hydrogen chloride. The hydrochloride was recrystallized from abs. ethanolzether (3:5) twice M.P. 205-206 C.
  • EXAMPLE 5 This example illustrates the preparation of 2-pyrrolidino-2,6'-n-butyroxylidide.
  • 2-pyrrolidino-2',6'-n-butyroxylidide A mixture of 2- bromo-2',6'-butyroxylidide (0.0463 mole), pyrrolidine (0.13 g. mole) and benzene (100 ml.) was refluxed for 21 hrs. The solvent and excess pyrrolidine were evaporated in vacuo leaving a partly solidifying residue that was dissolved in 1 N hydrochloric acid ml.). The acid solution was washed with ether (2X 50 ml.) whereafter it was made alkaline with 7 N sodium hydroxide and extracted with ether (3 X 50 ml.). The ether extract was dried (Na SO and the solvent evaporated in vacuo.
  • the hydrocloride was prepared by dissolving the residue in ether and adding a. sufficient amount of gaseous hydrogen chloride; yield 0.0414 mole. After two recrystallizations from 95% ethanol:ethyl acetate (1:1) the colorless crystals melted at 238-240 C. Calculated for C H N OC1: C, 64.7; H, 8.49; CI, 11.9. Found: C, 64.9; H, 8.59; Cl, 12.1. LR.
  • EXAMPLE 6 This example illustrates the preparation of Z-(N-ethyln-butylamino) 2,6' n butyroxylidide.
  • 2-n-butylamino 2,6 butyroxylidide A mixture of 2-iodo-2', butyroxylidide (0.0315 mole), n-butylamine (0.0945 mole) and anhydrous benzene (100 ml.) was refluxed for hrs. After cooling, the benzene and excess n-butylamine were evaporated in vacuum. The residue was taken up in 1 N hydrochloric acid, washed with ether (3X 25 ml.)., filtered, made alkaline to a pH of 9 with 7 N sodium hydroxide and extracted with ether (4X 25 ml.).
  • amide NH 2960 (s) and 2890 (ms) (CH and CH 2615-2595 (m, broad); 2505 (m, NH 1680 (s, amide I); 1594 (w, Ph); 1530 (s, amide II); 1470 (s); 1228 (m, amide III); 781 (m, 3 adjacent Ph hydrogens out of plane).
  • EXAMPLE 7 This example illustrates the preparation of Z-dimethylamino-2',6'-caproylxylidide.
  • 2-bromo 2',6 caproylxylidide A mixture of 2,6- xylidine (0.125 mole) and glacial acetic acid (115 ml.) was cooled to 10 C. in a 1 liter bottle and-2-bromocaproyl bromide (0.136 mole) was added and mixed rapidly. As fast as possible this was followed by a cool (50 C.) solution of sodium acetate trihydrate (45 g.) in water (190 ml.). The mixture was shaken for 45 min. and filtered.
  • 2-dimethylamino 2,6' caproylxylidide A mixture of 2-bromo-2,6-caproylxylidide (0.119 mole), dimethylamine (0.356 mole) and benzene (177 ml.) were heated in a pressure vessel for 22 hrs. at 100 C. After cooling the reaction mixture was filtered. The weight of the obtained dimethylammonium bromide indicated that 97% of the bromo compound had reacted. The filtrate was extracted with 4 N hydrochloric acid (1 X 50+2 25 ml.), the acid solution based out to pH 11 with 7 N sodium hydroxide and extracted with ether (3X 50 ml.). The combined ether extracts were dried (Na SO and evaporated in vacuo.
  • 2-pyrrolidino-2,6'-n-valeroxylidide A mixture of 2- iodo 2,6' n valeroxylidide (0.0754 mole), pyrrolidine (0.226 mole) and benzene (65 ml.) was heated in a pres sure vessel for 24 hrs. at C. After cooling, the benzene and excess pyrrolidine were evaporated in vacua. The residue was stirred with water ml.) for 30 min. and filtered. To the filtrate 7 N sodium hydroxide was added (pH 11) with stirring and after 30 min. the solid base was filtered, washed carefully and repeatedly with water and dried in vacuo.
  • A is Z-diethylamino-2',6'-n-butyroxylidide.
  • B is 2-(N-ethyl-n-propylamino)-2',6'-n-butyroxylidide.
  • C is the d-optical isomer of the racemic compound B.
  • D is the l-optical isomer of the racemic compound B.
  • E is 2-diethylamino-2,6'-n-valeroxylidide.
  • F is 2-pyrrolidino-2',6'-n-butyroxylidide.
  • Tables I through V contain comparative data on the duration of several of these local anaesthetic compounds
  • Table VI contains comparative data on the degree of tissue irritation of several of these local anaesthetic compounds
  • Tables VII and VIII contain comparative data on the acute toxicity of several of these local anaesthetic compounds.
  • Noam-Solutions did not contain epinephrine.
  • Irritation indices reported in Table VI are determined Norm-All solutions contained 12100,!00 epinephrine. the followmg manner:
  • a 2-alkyl-2-alkylamino-2',6'-acetoxylidide local .anaesthetic compound having the structural formula wherein R is ethyl, propyl or butyl; R and R are each separately seelcted from the group consisting of methyl, ethyl, propyl and butyl; R together with 'R is tetramethylene; the total sum of carbon atoms in R R and R is at least six; and the pharmaceutically acceptable salts thereof.
  • the local anaesthetic compound defined by claim 1 which is Z-diethylamino-Z,6'-n-butyroxylidide.
  • the local anaesthetic compound defined by claim 1 which is 2-(N-ethyl-n-propylamino)-2,6'-n-butyroxylidide.
  • the local anaesthetic compound defined by claim 1 which is 2-pyrrolidin0-2',6-n-butyroxylidide.
  • the local anaesthetic compound defined by claim 1 which is 2-(N-ethyl-n-butylamino)-2',6'-n-butyroxylidide.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

THE 2-ALKYL-2-ALKYLAMINO - 2'',6'' - ACETOXYLIDIDE COMPOUNDS ARE USEFUL AS LONG LASTING LOCAL ANAESTHETICS.

Description

United States Patent Us. (:1. 260-3263 Claims ABSTRACT OF THE DISCLOSURE The 2-alkyl-2-alkylamino 2',6 acetoxylidide compounds are useful as long lasting local anaesthetics.
This application is a continuation-in-part of our US. application Ser. No. 100,777, filed Dec. 22, 1970, now abandoned.
The present invention relates to 2-alkyl-2-alkylamino- 2',6-acetoxylidide local anaesthetic compounds.
Two acylxylidide local anaesthetic compounds which are commercially available are N-n-butylpipecolyl- 2,6- xylidide or bupivacaine sold under the trademark Marcaine having the structural formula O C H:
and diethylaminoaceto-2,6-Xy1idide or w diethylamino-Z, 6-dimethyl-acetanilide or lidocaine sold under the trademark Xylocaine having the structural formula CHzCHa CHzCHs CH3 However, while bupivacaine or Marcaine is a long lasting local anaesthetic, it has the drawback of being irritating to tissue and while lidocaine or Xylocaine is not irritating to tissue, it has the drawback of not being a long lasting local anaesthetic.
Other local anaesthetics which are commercially available include a-propylaminopropiono-Z-toluidide or prilocaine sold under the trademark Citanest; a-pyrrolidinoaceto-2,'6-xylidide or pyrrocaine sold under the trademarks Endocaine and *Dynacaine; and N-methylpipecolyl-2,6-xylidide or mepivacaine sold under the trademark Carbocaine. However, these local anaesthetics are of short action.
It is, therefore, the principal object of the present invention to provide compounds which generally have the combined properties of long lasting local anaesthetic effect or high local anaesthetic activity, a satisfactory low level of tissue irritation and a satisfactory low acute toxicity.
The compounds of the present invention are the 2- alkyl-2-alkylamino-2',6' acetoxylidide local anaesthetic compounds having the structural formula wherein R is ethyl, propyl or butyl; R and R may be the same or diiferent alkyl radicals and are methyl, ethyl,
propyl or butyl; R together with R is tetramethylene; the number of carbon atoms in [R R and 'R is totally at least six; and the pharmaceutically acceptable salts thereof. These compounds are racemic compounds and hence the local anaesthetic dor l-optical isomers are included within the scope of the present invention.
Representative compounds include the following: 2- diethylamino-Z,6'-n-butyroxylidide, which can be alternatively named 2-ethyl-2-diethylamino-2',6'-acetoxylidide,
having the structural formula CHzCHa NHCOHN z 2-(N-ethyl-n-propylamino)2',6-n-butyroxylidide, which can be alternatively named 2-ethyl-2(N-ethyl-n-propylamino)-2',6'-acetoxylidide, having the structural formula Z-diethylamino-Z,6'-n-valeroxylidide, which can be alternatively named 2-n-propyl-2-diethylamino-2',6'-acetoxy1- idide, having the structural formula 2-pyrrolidino-2',6'-n-butyroxylidide, which can be alternatively named 2-ethyl-2-pyrrolidino-2,6'-acetoxylidide, having the structural formula /CHa-CH I J) l CHr-CHI CH: c aGHz 2 (N ethyl-n-butylamino)-2',6'-n-butyroxylidide, which can be alternatively named 2-ethyl-2-(N-ethyl-n-butylamino)2,6-acetoxylidide, having the structural formula /C H: C H3 4) i C'HaCHzOHflJH; C H3 0 H2 0 H8 2-dimethylamino-2', 6'- c aproylxylidide, which can be alternatively named 2-n-butyI-Z-dimethylamino-Z,6' acetoxylidide, having the structural formula ternatively named 2-n-propyl-2-pyrrolidino-2',6'-acetoxylidide, having the structual formula i CHr-C H The compounds of the invention can be prepared in accordance with the following partial class reactions:
where R R and R are as stated above and X is a bromine or a chlorine atom. More detailed and other procedures of preparation are given in the representative examples hereinafter.
The racemic compounds may be resolved into their dand l-optical isomers by treatment with land d-tartaric acid.
The compounds of the invention are useful as local anaesthetics in the conventional manner and employing conventional dosages thereof. These bases may be conventionally used in the form of solutions of their pharmaceutically acceptable salts, e.g., the hydrochlorides, tartrates and citrates.
The invention will be further illustrated by the following examples:
EXAMPLE 1 This example illustrates the preparation of Z-diethylamino-2', -n-butyroxylidide or or. (diethylamino) nbutyro-2,6-xylidide.
(u-Bromo n butyryl chloride).-Redistilled thionyl chloride (2.40 moles) was added to a-bromo-n-butyric acid (1.20 moles) in a 1000 ml. flask attached to a reflux condenser and drying tube. The mixture was heated to refiux for 5 hours. Excess thionyl chloride was distilled off with the bath temperature up to 120 C. The reaction mixture was kept at 2530 C. for one hour at water pump vacuum, whereafter the bath temperature was raised slowly to 80 C., at which point the a-bromo-mbutyryl chloride started distilling; B.P. 48-50" C.; yield: 1.10 moles (92%). A product sufiiciently pure for the following reaction was obtained by omitting the vacuum distillation and allowing a stream of dry argon (or nitrogen) to pass through the u-bromo-n-butyryl chloride at 80100 C. for 1.5-2 hours after the main bulk of thionyl chloride had been distilled 01f.
(oz Bromo-n-butyryl-2,6-xylidide) .a-Bromo-n-butyryl chloride (1.005 moles) was added to a cold mixture (5-10 C.) of 2,6-xylidine (0.92 mole) and glacial acetic acid (814 ml.) in a four liter bottle, quickly mixed, and quickly followed by a cold solution of sodium acetate trihydrate (315.6 g.) in water (1610 ml.). The bottle was closed and shaken for 30 minutes. The precipitate was filtered and washed several times by slurrying in water to remove the acetic acid as etficently as possible. It was then dried in air or in vacuum; M.P. 198200 C.; yield: 0.74 mole (80%). Calculated for C H BrNO: C, 53.3; H, 5.97; Br, 29.6. Found: C, 53.3;H, 5.79; Br, 29.7.
[m (Diethylamino)-n-butyro-2,6-xylidide] .--a-BI'OI110- n butyryl 2,6 Xylidide (0.0148 mole), diethylamine (0.0444 mole), and anhydrous benzene (25 ml.) were heated at 100 C. for hours in a pressure vessel. After cooling, the diethylammonium bromide was filtered off and the benzene solution extracted with three 25 ml. portions of 1 M hydrochloric acid. The acid extract was washed with 25 ml. of ether and brought up to pH 10 with 7 M sodium hydroxide and extracted with four 25 ml. portions of ether. The ether extract was dried over anhydrous sodium sulfate, filtered and the ether evaporated under vacuum giving u-(diethylamino)-n-butyro- 2,6-xylidide (0.00499 mole, 33.7%) as a waxy solid. This was converted to its hydrochloride salt with ethereal hydrogen chloride, and the salt was recrystallized three times from a mixture of absolute ethanol and ether; M.P. 224.5- 226 C. (decomp.). Calculated for C H ClN Or C, 64.3; H, 9.11; N, 9.37. Found: C, 64.4; H, 9.12; N, 9.39. I.R. (KBr disc, hydrochloride) 1 3175 (s, NH amide), 2980 and 2938 (shoulder) (s, CH and CH 2577 (s, NH+), 2490 (s, NH+), 1685 (s, amide I), 1599 (w, Ph), 1530 (s, amide II), 1479 (s), 1232 (s, amide III), 787 (5, Ph 3 adjacent hydrogens out of plane) cm.- N.M.R. (CDCl base), 6 1.10 (t, 9H, CH -CE3), 1.602.10 (m, 2H, CHCH CH 2.18 (s, 6H, Ph CH 2.68 (q, 4H, NC CH 3.25 (t, 1H, COCH), 6.98 (s, 3H, Ph), 8.73 (s broad, 1H, NHCO). A gas chromatographic analysis of the compound showed the presence of one single peak.
EXAMPLE 2 This example illustrates the preparation of Z-(N-ethyln-propylamino) 2',6' butyroxylidide or a-(N-ethyl-n propylamino)-n-butyro-2,6-xylidide.
(a-Bromo-n-butyryl 2,6 xylidide).This compound was prepared as described in Example 1.
(a-Iodo-n-butyryl-2,6xylidide) .a Bromo-n-butyryl- 2,6-xylidide (224.7 g., 0.832 mole), powdered potassium iodide (191.2 g., 1.15 moles) and anhydrous methanol (1200 ml.) were mixed in a 3000 ml. flask equipped with reflux condenser, mechanical stirrer and heating mantle. After refluxing for 3 hours, the mixture was allowed to cool for 30 minutes with continued stirring, transferred with stirring to a beaker containing 2.5 liters distilled water and left for one hour. The precipitate was filtered and pressed as dry as possible. It was then transferred back to the beaker and carefully stirred with circa 1.5 liters distilled water and filtered again. This procedure was repeated until the filtrate was free from bromide and odide ion. The precipitate was then dried in air and/or in a desiccator. Yield: 243 g., M.P. 220-222 C. (decomp.).
The obtained preparation was almost colorless. Recrystalllzed from ethanol the product melted at 223.5 C. under decomposition.
The uncrystallized product contains some of the bromo compound but was sufliciently pure for the following step.
[a-(n-Propylamino)-nbutyro 2,6-xylidide].-Method (a): n-Propylamine (67.9 g., 1.15 moles) and a-iOdO-D- butyryl-2,6-xylidide (121.5 g., 0.383 mole) were mixed w th anhydrous benzene (1220 ml.) in a flask equipped with reflux condenser, mechanical stirrer and heating mantle and refluxed for 8 hours. The light yellow solution was filtered from a yellow precipitate which was washed thoroughly with ether. The precipitate (no C=O band in LR.) was discarded. The filtrate and washings were co)mb1ned and evaporated leaving a yellow residue (143.4 g.
The residue was treated with 380 ml. 1 M hydrochloric acid. An insoluble solid was filtered off and washed with ether. The acid filtrate was extracted with ether and an additional precipitated solid was filtered 011 and combined Wll'h the primarily obtained insoluble solid. The weight of the combined solid fractions was 156.2 g. (I). The acid filtrate (II) was washed with four additional portions of ether. The solid fraction I was refluxed with anhydrous benzene, filtered, and washed with hot benzene and ether. The combined benzene and ether extracts from these operations contained 6.8 g. residue and was discarded. The solid fraction I and the acid solution II were corn-t bined and based out with 7 M NaOH and the freed base was extracted into ether. After drying over anhydrous sodium sulfate the ether extract was filtered and evaporated yielding 93 g. of a partly solidifying marooncolored residue.
This residue was dissolved in 80 ml. of ether in a separatory funnel and equilibrated with 200 ml. phosphate buffer so that the pH at equilibrium was 7.3. Keeping the pH at 7.3 the buffer solution was extracted three more times with 80 ml. portions of ether.
The ether extracts yielded 79.2 g. of a base that contained mainly the desired compound and which was sufficiently pure for the next step.
From the bulfer solution 6.3 g. of an oil could be obtained on raising the pH to 11 and extracting with ether. This fraction contained mainly the fl-substituted isomer, and was discarded.
Method (b): u-Bromo-n-butyryl 2,6 xylidide (63.1 millimoles), n-propylamine (254 millimoles), sodium iodide (63.1 millimoles), and absolute ethanol (180 ml.) were refluxed for 6.5 hours. The alcohol was evaporated in vacuo and the residue was mixed with 0.5 M HCl (200 ml.). The suspension was washed with two 100 ml. portions of ether, the pH adjusted to 11 with 7 M NaOH and the mixture extracted three times with 100 ml. portions of ether. After drying over anhydrous sodium sulfate the ether was evaporated leaving a residue of the amine. Yield: 51.0 millimoles (81%). The hydrochloride hydrate was prepared from the base with ethereal hydrogen chloride and addition of water. Recrystallized from ethanol/ether it melted at 199-1995 C. Calculated for the base (C H N O): C, 72.5; H, 9.74; N, 11.3. Found: C, 72.5; H, 9.81; N, 11.2.
[a-(N-ethyl-n-propylamino)-n-butyro 2,6-xylidide].- a-(n-Propylamino)-n-butyro-2,6-xylidide (0.243 mole) and freshly distilled diethyl sulfate (1.6 moles) were mixed in a flask equipped with reflux condenser, drying tube and stirrer. The mixture was stirred for 5 hours at 90 C. After cooling, water (110 ml.) was added with stirring for fifteen minutes followed by 4 M HCl (110 ml.). The solution was washed with ether (3x 100 ml.) and made alkaline with 7 M NaOH to pH 10-11. The freed base was taken up in ether (3 100 ml.); the extracts were dried over sodium sulfate, filtered and evaporated. The residue was dissolved in absolute ether (200 ml.) and the hydrochloride prepared by addition of ethereal hydrogen chloride. The precipitate was filtered, washed with ether, and recrystallized twice from absolute ethanol/ether and from isopropanol/isopropylether; M.P. 203-203.5 C.; yield: 0.126 mole (52%). Calculated for C H ClN O: C, 65.3; H, 9.34; Cl, 11.3. Found: C, 65.2; H, 9.29; Cl, 11.3. LR. (KBr disc, hydrochloride) 11 3175 (s, amide NH), 2970 and 2940 (s, CH and CH 2580 (s, NH+), 2505 (s, NH 1680 (s, amide I), 1595 (w, Ph), 1531 (s, amide II), 1474 (s), 1227 (s, amide III), 778 (s, Ph 3 adjacent hydrogens out of plane) cmr N.M.R. (CDCl base) 6 1.06 (t, CH CH 1.26 (t, CH Cg [9H for the two triplets], 1.58-2.48 (m, 4H, cg cm), 2.53 (s, 6H, PhCHs), 2.82-3.30 (m, 4H, NCH2 a 3.72 (t, 1H, COCH), 7.98 (s, 3H, Ph). A gas chromatrographic analysis showed one single peak.
EXAMPLE 3 The racemic compound of Example 2 was resolved into the dand l-optical isomers by the following procedure:
The racemate of a-(N-ethyl-n-proplamino)-n-butyro- 2,6-xylidide base (9.73 g., 0.3519 mole) was dissolved in a mixture of l-tartaric acid (5.28 g., 0.3519 mole) and 19.5 ml. water by gentle heating. After filtering, the solution was cooled and left at 4 C. The crystals formed were filtered cold. The mother liquor was concentrated to about half its volume and a second crop was obtained. The combined crops (I) were recrystallized repeatedly from water until constant optical rotation was obtained [a] =8.3. The mother liquid was made alkaline with 7 M sodium hydroxide and extracted with ether. The ether was evaporated and 3.18 g. 0.0115 mole) residual base was obtained which was dissolved in a solution of d-t-artaric acid (1.73 g., 0.0115 mole) in 6.4 ml. water with heating. From the cold solution (4 C.) crystals (II) were obtained which were recrystallized repeatedly from water until constant rotation was obtained,
The bases were liberated from the two tartrates with sodium hydroxide in water. The bases from (I) and (II) had specific rotation of +34.1 and -32.8, respectively. The rotation of their hydrochlorides were +6.2 and -6.2, respectively, after recrystallization from abs. ethanol-ether. Their melting points were identical, 184- 185 C.
The racemic compounds of Examples 1 and 4-8 can be resolved into the dand l-optical isomers thereof by a procedure similar to the one of Example 3.
EXAMPLE 4 This example illustrates the preparation of Z-diethylamino-2',6-n-valeroxylidide.
2-bromo-2,6-n-valeroxylidide.-In a 2 liter bottle were mixed 2,6-xylidine (0.347 mole) and glacial acetic acid (310 ml.). The mixture was cooled to 12 C. and 2-bromo-n-valeryl chloride (0.349 mole) was added rap idly. After quick mixing a precooled (5 C.) solution of sodium acetate trihydrate g.) in water (340 ml.) was immediately added and the mixture was shaken for circa 30 minutes. The solid was filtered and washed carefully and repeatedly with water until the filtrate was free from bromide. After drying in a desiccator over potassium hydroxide flakes the solid (0.345 mole) melted at 189-1905 C. After recrystallization from ethanol the melting point of the colorless crystals was 190-190.5 C. Yield: 65-78%. Calculated for C H BrNO: C, 54.9; H, 6.38; Br, 28.1. Found: C, 54.9; H, 6.33; Br, 28.2.
2-diethylamino-Z,6'-n-valeroxylidide.-A mixture of 2-bromo-2,6'-n-valeroxylidide (0.176 mole), diethylamine (0.528 mole), and benzene (125 ml.) was placed in a pressure vessel and heated to C. for 35 hours. After cooling, the dark brown content was filtered and the solid (23.2 g. of diethylammonium bromide) washed carefully with benzene. The filtrate was extracted with 4 N hydrochloric acid (3 X 50 ml.), the acid extract washed with ether (3X 50 ml.), and based out with 7 N sodium hydroxide under cooling and stirring and in the presence of ether (100 ml.). After two further extractions with ether (2X 50 ml.) the combined ether extracts were dried (Na SO and the ether evaporated leaving 16.5 g. of residue. The hydrochloride was prepared from the residue by dissolving it in ether and adding ethereal hydrogen chloride. The hydrochloride was recrystallized from abs. ethanolzether (3:5) twice M.P. 205-206 C. Calculated for clqHggclNzo: C, 65.3; H, 9.34; N, 8.95. Found: C, 65.2; H, 9.49; N, 9.15. Only one distinct peak was obtained on gas chromatography of the salt. I.R. (KBr disc, hydrochloride): 3170 (mw, NH amide); 2968 and 2930 (m, CH and CH 2560 (m, NH+); 1677 (s, amide I); 1593 (w, Ph); 1528 (s, amide II); 1472 and 1433 (ms); 1230 (mw, amide IH); 775 (m, 3 adjacent pH hydrogens out of plane).
EXAMPLE 5 This example illustrates the preparation of 2-pyrrolidino-2,6'-n-butyroxylidide.
2-pyrrolidino-2',6'-n-butyroxylidide.-A mixture of 2- bromo-2',6'-butyroxylidide (0.0463 mole), pyrrolidine (0.13 g. mole) and benzene (100 ml.) was refluxed for 21 hrs. The solvent and excess pyrrolidine were evaporated in vacuo leaving a partly solidifying residue that was dissolved in 1 N hydrochloric acid ml.). The acid solution was washed with ether (2X 50 ml.) whereafter it was made alkaline with 7 N sodium hydroxide and extracted with ether (3 X 50 ml.). The ether extract was dried (Na SO and the solvent evaporated in vacuo. The hydrocloride was prepared by dissolving the residue in ether and adding a. sufficient amount of gaseous hydrogen chloride; yield 0.0414 mole. After two recrystallizations from 95% ethanol:ethyl acetate (1:1) the colorless crystals melted at 238-240 C. Calculated for C H N OC1: C, 64.7; H, 8.49; CI, 11.9. Found: C, 64.9; H, 8.59; Cl, 12.1. LR. (KBr disc, hydrochloride): 3450 (in, broad); 3175 (ms, amide NH); 2965 and 2927 (ms, CH and CH 2670, 2630, and 2600 (ms); 2475 (mw, NH+); 1680 (s, amide I); 1529 (w, Ph); 1525 (s, amide II); 1469 (ms); 1227 (m, amide III); 781 (ms, 3 adjacent pH hydrogens out of plane).
EXAMPLE 6 This example illustrates the preparation of Z-(N-ethyln-butylamino) 2,6' n butyroxylidide.
2-n-butylamino 2,6 butyroxylidide.-A mixture of 2-iodo-2', butyroxylidide (0.0315 mole), n-butylamine (0.0945 mole) and anhydrous benzene (100 ml.) was refluxed for hrs. After cooling, the benzene and excess n-butylamine were evaporated in vacuum. The residue was taken up in 1 N hydrochloric acid, washed with ether (3X 25 ml.)., filtered, made alkaline to a pH of 9 with 7 N sodium hydroxide and extracted with ether (4X 25 ml.). The ether extract was dried (Na SO and the ether was then evaporated in vacuo leaving a colorless oil (0.0153 mole). (This oil is sufficiently pure for the ethylation step described below.) A hydrochloride was prepared from the oily' base in anhydrous ether by addition of an ethereal hydrogen chloride solution. The formed product was not crystallizing readily from a number of solvents. On dissolving in water, crystals appeared on standing. The formed hydrochloride hydrate was recrystallized from aqueous ethyl acetate, M.P. 92-95 'C. Calculated for C H ClN O-H O: H O, 5.71. Found: 5.73 (Karl Fischer). A sample was dried at high vacuum and elevated temperature. Calculated for C H ClN O: C, 64.3; H, 9.11; CI, 11.9. Found: C, 64.1; H, 9.26; Cl, 11.8.
2-(N ethyl n butylamino)-2',6'-n-butyroxylidide.- A mixture of 2-n-butylamino 2',6' butyroxylidide [the oily unpurified base (0.0153 mole) mentioned above] and diethyl sulfate (0.0996 mole) was heated at 90 C. for 5 hrs. After cooling, the clear amber-colored solution was mixed with 10 ml. of water, stirred for min. and mixed with 10 ml. of 4 N hydrochloric acid. The acid solution was washed with ether allowing the phases to separate completely, the upper ether layer being discarded each time. The pH was adjusted to 11 with 7 N sodium hydroxide and the separating base taken up in ether (4X 30 ml.). After drying (Na SO the ether was evaporated leaving a residue of crude base (0.0395 mole). The hydrochloride was prepared by dissolving the residue in anhydrous ether and adding ethereal hydrogen chloride to the solution. Recrystallized from abs. alcohol: ether, colorless crystals were obtained melting at 202.5-204.5 C. Calculated for C I-I ClN O: C, 66.1; H, 9.56; Cl, 10.8. Found: C, 66.1; H, 9.71; Cl, 11.1. LR. (KBr disc, hydrochloride): 3160 (ms. amide NH); 2960 (s) and 2890 (ms) (CH and CH 2615-2595 (m, broad); 2505 (m, NH 1680 (s, amide I); 1594 (w, Ph); 1530 (s, amide II); 1470 (s); 1228 (m, amide III); 781 (m, 3 adjacent Ph hydrogens out of plane).
EXAMPLE 7 This example illustrates the preparation of Z-dimethylamino-2',6'-caproylxylidide.
2-bromo 2',6 caproylxylidide.-A mixture of 2,6- xylidine (0.125 mole) and glacial acetic acid (115 ml.) was cooled to 10 C. in a 1 liter bottle and-2-bromocaproyl bromide (0.136 mole) was added and mixed rapidly. As fast as possible this was followed by a cool (50 C.) solution of sodium acetate trihydrate (45 g.) in water (190 ml.). The mixture was shaken for 45 min. and filtered.
The precipitate was washed carefully and repeatedly with water until free from bromide ions. It was then dried in a desiccator over potassium hydroxide flakes and recrystallized from methanolzwater (approx. 15:1) twice; M.P. 167-169 C. Yield: 67%. This material was sufiiciently pure for the subsequent reaction. The pure compound (one further recrystallization) had a M.P. of 168.5-169 C. Calculated for C H BrNO: C, 56.4; H, 6.76; Br, 26.8. Found: C, 56.2; H, 6.40; Br, 25.9.
2-dimethylamino 2,6' caproylxylidide.-A mixture of 2-bromo-2,6-caproylxylidide (0.119 mole), dimethylamine (0.356 mole) and benzene (177 ml.) were heated in a pressure vessel for 22 hrs. at 100 C. After cooling the reaction mixture was filtered. The weight of the obtained dimethylammonium bromide indicated that 97% of the bromo compound had reacted. The filtrate was extracted with 4 N hydrochloric acid (1 X 50+2 25 ml.), the acid solution based out to pH 11 with 7 N sodium hydroxide and extracted with ether (3X 50 ml.). The combined ether extracts were dried (Na SO and evaporated in vacuo. From the residue the hydrochloride was prepared with ethereal hydrogen chloride. It was recrystallized from abs. alcoholzether (1:8) twice, yielding colorless crystals (0.0992 mole) melting at 193.5- 194.5 C. Calculated for CmHgqClNgOZ C, 64.3; H, 9.10; N, 9.37; Cl, 11.9. Found: C, 64.2; H, 9.04; N, 9.52; Cl, 12.0. I.R. (KBr disc, hydrochloride): 3185 (m, amide NH); 2950 and 2920 (ms-m, CH and CH 2450 (ms, NH' 1682 (s, amide I); 1591 (w, Ph); 1530 (s, amide II); 1470 (s); 1236 (mw, amide III); 776 (m, 3 adjacent Ph hydrogens out of plane EXAMPLE 8 This example illustrates the preparation of 2-pyrrolidino-2',6'-n-valeroxylidide.
2-iodo-2',6-n-valeroxylidide.A mixture of 2-bromo- 2',6-n-valeroxylidide (0.137 mole), potassium iodide (0.274 mole) and dry methanol (375 ml.) was refluxed under stirring for 3 hrs. After cooling, 1 liter of water was added to the yellow-colored reaction mixture and it was left with stirring for 15 min. The precipitate was filtered, washed repeatedly with water until the filtrate was free of halogenides, and dried. After recrystallization from ethanol it melted at 1965-1975" C.; yield 0.105 mole of a product sufiiciently pure for the next synthetic step. Another recrystallization brought the M.P. to 197- 198 C. Calculated for C H INO: C, 47.1; H, 5.48; I, 38.3. Found: C, 47.3; H, 5.36; I, 38.2.
2-pyrrolidino-2,6'-n-valeroxylidide.-A mixture of 2- iodo 2,6' n valeroxylidide (0.0754 mole), pyrrolidine (0.226 mole) and benzene (65 ml.) was heated in a pres sure vessel for 24 hrs. at C. After cooling, the benzene and excess pyrrolidine were evaporated in vacua. The residue was stirred with water ml.) for 30 min. and filtered. To the filtrate 7 N sodium hydroxide was added (pH 11) with stirring and after 30 min. the solid base was filtered, washed carefully and repeatedly with water and dried in vacuo. The crude base (14 g.) was recrystallized from aqueous ethanol to constant M.P. (126-1275 C.); yield 4.9 g. From the mother liquors another 2.7 g. were obtained. Total yield: 37%. Calculated for C H N O: C, 74.4; H, 9.55; N, 10.2. Found:
C, 74.1; H, 9.66; N, 10.4. I.R. (KBr disc, base): 3210 (s NH amide); 2933 (s), 2915 (ms) (CH and CH 1645 (s, amide I); 1593 (w, Ph); 1529 (s, amide II); 1478 and 1465 (ms); 770 (s, 3 adjacent Ph hydrogens out of plane).
In the tables presented below the following code designations have been used:
A is Z-diethylamino-2',6'-n-butyroxylidide.
B is 2-(N-ethyl-n-propylamino)-2',6'-n-butyroxylidide. C is the d-optical isomer of the racemic compound B.
D is the l-optical isomer of the racemic compound B.
E is 2-diethylamino-2,6'-n-valeroxylidide.
F is 2-pyrrolidino-2',6'-n-butyroxylidide.
i CHIC/HZ Tables I through V contain comparative data on the duration of several of these local anaesthetic compounds, Table VI contains comparative data on the degree of tissue irritation of several of these local anaesthetic compounds while Tables VII and VIII contain comparative data on the acute toxicity of several of these local anaesthetic compounds. i
TABLE V.PERIDURAL ANAEST'HESIA IN THE DOG 1 Duration of block of support of weight in minutes Percent concentrate base E X Y Mature male beagles are surgically prepared by implantation of a cannula into a lumbar vertebra so that drug solutions (5 ml.) may be administered into the peridural space. Aiter administration of local anaesthetic solutions, the animals are examined at intervals for duraation of motor block (support of weight).
Nora-A11 solutions contained 1:100,000 epinephrine;
TABLE VI.IRRITATION STUDIES: RABBIT INTRADE RMAL WHEALS 1 Percent Irritation index concentrate as base A B X Y Z 'lest method given in Truant, A.P.: Arch. Int. Pharmacodyn. 115: 483-497 (1958), which is incorporated by reference herein.
NOTE.-SO1i1i;i0l1S did not contain epinephrine.
TABLE I.--RAT SCIATIC NERVE BLOCKS 1 Duration in minutes =i= standard deviation Percent concentrate as base A B C D E F G H X Y Z 279116 114:1:23 160=i=27 140i12 135:};18 236:5538 126=e13 212=e34 1235:10 l18:i:15
313 97516 191=|=57 179:1:27 1785:18 3d mile 213 16239 126=i=21 172:1:31 2s7=|=se zeszhae 1 180;};43 2803:42 185=i=28 146=l=l8 1 Test method given in Truant, A.P.: Arch. Int. Pharmacodyn. 2 Some animals blocked 12 hrs.
115: 483497 (1958), which is incorporated by reference herein. solutions contained 1:100000 epinephrine.
TABLE II.GUINEA PIG INTRADERMAL WHEALS TABLE VIL-ACUTE TOXICITY IN FEMALE MICE Percent Duration in minutes=i=standard deviation LD o and 95% Fieller confidence concentrate limits: rug/kg. as base as base A B X Y Z Compound Intraperitoneal Intravenous 0.125 15e=i=11 955:8 154:1:15 182:i=4 7a=|=9 96d=l2 54(461l7) 9.4(8. 2-11) 110=i=4 1745:12 252=i=5 110413 1013:12 62(5382) 5.8(5. 1-6. 5) 169%:8 232=l=11 3i410 i17=i=6 117:1:14 15.9(14. 0-18. 6)
l2li12 1665:19 .4-6. Test method given in Bulbring, E. and Wajda, I.: J. Pharmacol. 9) Exp. Therap. 85: 78-84 (1945), which is incorporated by reference herein. 11. 3(9. 2-13. 9) Nora-All solutions contained 1:1000,000 epinephrine. 6. 4(5. 5-7. 3) 25 (22-33;
Noam-Solutions did not contain epinephrine.
TABLE III.-PERIDURAL ANAESTHESIA IN THE CAT TABLE TOXICITY IN MALE Duration of block of support of weight in minutesistandard deviation LDio and 95% Fielggiiggigfidence limits. mg.kg. Percent concentrate ase A B X Y sex A B X Male 136(102-172 71(53-90) 1.0.- 1:135:24 308z|=2l 2 296=i=77 2D 2365:26 88 5:10 Female 94(73-120) 124(98-160; 7 3) 1 Test method given in Duce, B. R., Zelechowski, K., Camougis, contained 1:200'000 epinephrine 1G. and Stniiitl, E.fR.: Brit. J' Anaesth. 41: 579-587 (1969), which is 1100 ore e re 8191106 erein.
IExie efiect s observed at this concentration. Irritation indices reported in Table VI are determined Norm-All solutions contained 12100,!)00 epinephrine. the followmg manner:
Wheals are made on the shaved backs of albino rabbits by intradermal injection of aqueous solutions of the agents. Twenty-four hours later each wheal is graded for: presence and severity of erythema, presence and severity TABLE IV-PERIDURAL ggi IN THE GUINEA of edema, and presence or absence" of necrotic tissue in the wheel. The grading is done on an arbitrary numerical Duration of block of support of weight in W u minutes 5: standard deviation scale, and a mean irritation ndex is calculated for Percent concentrate all wheels at a given concentration. base E G X Y The test method employed for the acute toxicity studies 39M 465:8 38=l=7 10 reported in Tables VII and VIII was as follows: 2%; 5? 351 iii; 79 Sexually mature male or female animals are used. 1 as m I v B 29 H 6 Animals are divided into groups of 10 and dosed with 1 Testmethod given nTan an now et. cs. 48 19 8 r whichismcorpomed by reference harem I f drug solution or vehicle. After being dosed, animals are 2 Three animals died 5 minutes post-injection and one animal did not observed at intervals for several hours for overt effects and fatalities. Survivors are housed as groups according Norn.-Al1 solutions contained 1:100,000 epinephrine.
to dose level and checked once daily for the duration of 1 1 the study in order to determine whether or not delayed fatalities occur.
LD s and 95 Fieller confidence limits (or 95% approximate limits) are calculated by the Minimum Logit Chi Square Method of Berkson, I. Am. Stat. Assoc, 481565 (1953).
The comparative data presented in Tables I-VIII above establish that-the racemic compounds of the invention generally are appreciably longer lasting local anaesthetics, particularly at use concentrations of 1% or 2%, than are the comparative homologous compounds Y and Z and yet they have a satisfactory low level of tissue irritation and a satisfactory low acute toxicity.
What is claimed is:
'1. A 2-alkyl-2-alkylamino-2',6'-acetoxylidide local .anaesthetic compound having the structural formula wherein R is ethyl, propyl or butyl; R and R are each separately seelcted from the group consisting of methyl, ethyl, propyl and butyl; R together with 'R is tetramethylene; the total sum of carbon atoms in R R and R is at least six; and the pharmaceutically acceptable salts thereof.
2. The local anaesthetic compound defined by claim 1 which is Z-diethylamino-Z,6'-n-butyroxylidide.
3. The local anaesthetic compound defined by claim 1 which is 2-(N-ethyl-n-propylamino)-2,6'-n-butyroxylidide. t
4. The local anaesthetic compound defined by claim 1 which is 2-diethylamino-2,6'-n-valeroxylidide.
5. The local anaesthetic compound defined by claim 1 which is 2-pyrrolidin0-2',6-n-butyroxylidide.
6. The local anaesthetic compound defined by claim 1 which is 2-(N-ethyl-n-butylamino)-2',6'-n-butyroxylidide.
7. The local anaesthetic compound defined by claim 1 which is Z-dimethylamino-Z',6-caproylxylidide.
8. The local anaesthetic compound defined by claim 1 which is Z-pyrrolidino-Z',6'-n-valeroxylidide.
9. The d-optical isomers of the compounds described in claim 1.
10. The l-optical isomers of the compounds described in claim 1.
References Cited UNITED STATES PATENTS 3,544,587 12 /1970 Brown 260326.3
3,542,850 11/1970 Jansen et a1. 260471 2,904,586 9/1959 Ruschig et al. 260--500 OTHER REFERENCES Lofgren et al.: Svensk. Kem. T id., vol. 58 (1946), 206- 217. t t
Schonenberger et al.: Archiv der Pharmazie, 301 Bd JOSEPH A. NARCAVAGE, Primary Examiner US. Cl. X.R.
US00164022A 1970-12-22 1971-07-19 Acylxylidide local anaesthetics Expired - Lifetime US3812147A (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
US00164022A US3812147A (en) 1970-12-22 1971-07-19 Acylxylidide local anaesthetics
SE7115656A SE393374B (en) 1970-12-22 1971-12-07 PROCEDURE FOR THE PREPARATION OF 2-ALKYL-2-DIALKYLAMINO-2, '6'-ACETOXYLIDIDES WITH LOCAL AESTHETIC EFFECT
BE776656A BE776656A (en) 1970-12-22 1971-12-14 LOCAL ACYLXYLIDIDE ANESTHETICS
SU1726195A SU419023A3 (en) 1970-12-22 1971-12-15 METHOD FOR OBTAINING ACYLIC XYLIDIDES
HUAA690A HU163373B (en) 1970-12-22 1971-12-16
DK619771AA DK139814B (en) 1970-12-22 1971-12-17 Analogous process for the preparation of locally anesthetically active 2-alkyl-2- (dialkylamino- or pyrrolidino) -2 ', 6'-acetoxylidides in optically active or racemic form or pharmaceutically acceptable salts thereof.
NO4669/71A NO135934C (en) 1970-12-22 1971-12-17
DE2162744A DE2162744C3 (en) 1970-12-22 1971-12-17 N, N-disubstituted α-amino carboxylic acid (2 ', 6'-xylidides) and local anesthetic agents containing these compounds
IT54845/71A IT1066334B (en) 1970-12-22 1971-12-18 LOCAL AN AESTHETIC COMPOSITION OF 2-ALCHIL-2-ALCHIL AMINO 2 ', 6' ACETOXYLIDIDE AND RELATED PRODUCTION PROCESS
AU37099/71A AU468489B2 (en) 1970-12-22 1971-12-20 Acyl xylidide local anaesthetics
AT1089671A AT319205B (en) 1970-12-22 1971-12-20 Process for the preparation of new racemic or optically active 2-alkyl-2-dialkylaminoacet-2 ', 6'-xylidides and their salts
IE1609/71A IE35909B1 (en) 1970-12-22 1971-12-20 Acylxylidide local anaesthetics
BR8466/71A BR7108466D0 (en) 1970-12-22 1971-12-21 LOCAL ANESTHETICS AND ACYLXYLIDIDES AND THE PROCESS OF THEIR PREPARATION
AR239721A AR193840A1 (en) 1970-12-22 1971-12-21 A PROCEDURE FOR THE PREPARATION OF 2-ALKYL-2-ALKYLAMINE-2 ', 6'-ACETOXYLIDIDE COMPOUNDS
DD159785A DD99779A5 (en) 1970-12-22 1971-12-21
GB5937771A GB1369259A (en) 1970-12-22 1971-12-21 Acylxylidide local anaesthetics
FR7145983A FR2118985B1 (en) 1970-12-22 1971-12-21
PL1971152331A PL83097B1 (en) 1970-12-22 1971-12-21
CA130,662A CA943966A (en) 1970-12-22 1971-12-21 Acyl xylidide local anaesthetics
ES398210A ES398210A1 (en) 1970-12-22 1971-12-21 Acylxylidide local anaesthetics
CH1862971A CH573396A5 (en) 1970-12-22 1971-12-21 Acylxylidides - as local anaesthetics
JP10453571A JPS5644063B1 (en) 1970-12-22 1971-12-22
NLAANVRAGE7117644,A NL172149C (en) 1970-12-22 1971-12-22 PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATION WITH A LOCAL ANESTHETIC EFFECT CONTAINING A DIALKYLAMINO-2 ', 6'-BUTYROXYLIDIDE AND / OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREFORE PREPARED FOR THESE PREPARED IN THESE PREPARATION OF DIALKYLAMINO-2 ', 6'-BUTYROXILIDES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS.
FI3658/71A FI55027C (en) 1970-12-22 1971-12-22 FREQUENCY REQUIREMENT FOR LOCAL LIQUID DISCHARGE 2-ALKYL-2-ALKYLAMINO-2 ', 6'-ACETOXYLIDIDER
US447680A US3862321A (en) 1971-07-19 1974-03-04 Acyl xylidide local anaesthetics
ES425626A ES425626A1 (en) 1970-12-22 1974-04-24 Acylxylidide local anaesthetics
NL8204126A NL8204126A (en) 1970-12-22 1982-10-26 PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATION WITH A LOCAL ANESTHETIC EFFECT CONTAINING A DIALYLAMINO-2 ', 6'-ACETOXYLIDIDE AND / OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND THE PREPARED PROPERTY OF THESE PREPARED THEREFORE THEREFORE DIALKYLAMINO-2 ', 6'ACETOXYLIDIDS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10077770A 1970-12-22 1970-12-22
US00164022A US3812147A (en) 1970-12-22 1971-07-19 Acylxylidide local anaesthetics

Publications (1)

Publication Number Publication Date
US3812147A true US3812147A (en) 1974-05-21

Family

ID=26797539

Family Applications (1)

Application Number Title Priority Date Filing Date
US00164022A Expired - Lifetime US3812147A (en) 1970-12-22 1971-07-19 Acylxylidide local anaesthetics

Country Status (23)

Country Link
US (1) US3812147A (en)
JP (1) JPS5644063B1 (en)
AR (1) AR193840A1 (en)
AT (1) AT319205B (en)
AU (1) AU468489B2 (en)
BE (1) BE776656A (en)
BR (1) BR7108466D0 (en)
CA (1) CA943966A (en)
DD (1) DD99779A5 (en)
DE (1) DE2162744C3 (en)
DK (1) DK139814B (en)
ES (2) ES398210A1 (en)
FI (1) FI55027C (en)
FR (1) FR2118985B1 (en)
GB (1) GB1369259A (en)
HU (1) HU163373B (en)
IE (1) IE35909B1 (en)
IT (1) IT1066334B (en)
NL (2) NL172149C (en)
NO (1) NO135934C (en)
PL (1) PL83097B1 (en)
SE (1) SE393374B (en)
SU (1) SU419023A3 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957996A (en) * 1971-12-08 1976-05-18 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic compositions
US3966934A (en) * 1971-12-08 1976-06-29 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US3975443A (en) * 1972-06-06 1976-08-17 Allen & Hanburys Limited 1-(3,4-dichlorobenzamidomethyl)-cyclohexyldimethylamine
US4125730A (en) * 1975-08-22 1978-11-14 Banyu Pharmaceutical Co., Ltd. Preparation of -aminoalkanoic acid arylamides
US4237068A (en) * 1971-07-28 1980-12-02 Astra Pharmaceutical Products, Inc. Primary aminoacylanilides
US4891058A (en) * 1988-07-18 1990-01-02 Ici Americas Inc. 1-alkyl-3-aryl imidazolidine-2,4-diones and herbicidal use
US10729664B2 (en) 2009-07-10 2020-08-04 President And Fellows Of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10842798B1 (en) 2019-11-06 2020-11-24 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10927096B2 (en) 2019-03-11 2021-02-23 Nocion Therapeutics, Inc. Ester substituted ion channel blockers and methods for use
US10934263B2 (en) 2019-03-11 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10968179B2 (en) 2019-03-11 2021-04-06 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11021443B2 (en) 2015-08-03 2021-06-01 President And Fellows Of Harvard College Charged ion channel blockers and methods for use
US11332446B2 (en) 2020-03-11 2022-05-17 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0062322A1 (en) * 1981-04-03 1982-10-13 The B.F. GOODRICH Company Improved process for synthesis of hindered amine stabilizers for polymeric materials
SE8900685D0 (en) * 1989-02-28 1989-02-28 Astra Ab NEW COMPOUNDS
US5153226A (en) * 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
DK2101819T3 (en) 2006-11-20 2013-04-29 Harvard College Methods, compositions and kits for the treatment of pain and pruritis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1124837A (en) * 1966-06-03 1968-08-21 Wyeth John & Brother Ltd Substituted anilides

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237068A (en) * 1971-07-28 1980-12-02 Astra Pharmaceutical Products, Inc. Primary aminoacylanilides
US3957996A (en) * 1971-12-08 1976-05-18 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic compositions
US3966934A (en) * 1971-12-08 1976-06-29 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US3975443A (en) * 1972-06-06 1976-08-17 Allen & Hanburys Limited 1-(3,4-dichlorobenzamidomethyl)-cyclohexyldimethylamine
US4125730A (en) * 1975-08-22 1978-11-14 Banyu Pharmaceutical Co., Ltd. Preparation of -aminoalkanoic acid arylamides
US4891058A (en) * 1988-07-18 1990-01-02 Ici Americas Inc. 1-alkyl-3-aryl imidazolidine-2,4-diones and herbicidal use
US10729664B2 (en) 2009-07-10 2020-08-04 President And Fellows Of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
US11021443B2 (en) 2015-08-03 2021-06-01 President And Fellows Of Harvard College Charged ion channel blockers and methods for use
US10968179B2 (en) 2019-03-11 2021-04-06 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11643404B2 (en) 2019-03-11 2023-05-09 Nocion Therapeutics, Inc. Ester substituted ion channel blockers and methods for use
US10927096B2 (en) 2019-03-11 2021-02-23 Nocion Therapeutics, Inc. Ester substituted ion channel blockers and methods for use
US10934263B2 (en) 2019-03-11 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11603355B2 (en) 2019-03-11 2023-03-14 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11512058B2 (en) 2019-03-11 2022-11-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11377422B2 (en) 2019-03-11 2022-07-05 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10842798B1 (en) 2019-11-06 2020-11-24 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11696912B2 (en) 2019-11-06 2023-07-11 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11332446B2 (en) 2020-03-11 2022-05-17 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use

Also Published As

Publication number Publication date
ES425626A1 (en) 1976-06-16
DE2162744C3 (en) 1982-04-15
HU163373B (en) 1973-08-28
IE35909L (en) 1972-06-22
DK139814B (en) 1979-04-23
SE393374B (en) 1977-05-09
AU3709971A (en) 1973-06-28
AU468489B2 (en) 1976-01-15
IE35909B1 (en) 1976-06-23
DD99779A5 (en) 1973-08-20
JPS5644063B1 (en) 1981-10-16
NL172149C (en) 1983-07-18
NO135934B (en) 1977-03-21
PL83097B1 (en) 1975-12-31
ES398210A1 (en) 1975-03-16
NO135934C (en) 1977-06-29
DE2162744A1 (en) 1972-07-06
AR193840A1 (en) 1973-05-31
NL8204126A (en) 1983-02-01
BR7108466D0 (en) 1973-06-14
BE776656A (en) 1972-06-14
CA943966A (en) 1974-03-19
DK139814C (en) 1979-10-01
NL172149B (en) 1983-02-16
GB1369259A (en) 1974-10-23
FI55027B (en) 1979-01-31
FI55027C (en) 1979-05-10
FR2118985A1 (en) 1972-08-04
AT319205B (en) 1974-12-10
DE2162744B2 (en) 1981-07-02
SU419023A3 (en) 1974-03-05
NL7117644A (en) 1972-06-26
IT1066334B (en) 1985-03-04
FR2118985B1 (en) 1975-12-26

Similar Documents

Publication Publication Date Title
US3812147A (en) Acylxylidide local anaesthetics
US4018895A (en) Aryloxyphenylpropylamines in treating depression
US4194009A (en) Aryloxyphenylpropylamines for obtaining a psychotropic effect
CA1051034A (en) Aryloxyphenylpropylamines
US4973755A (en) Stable solvent adducts of Z-1-(p-β-dimethylaminoethoxy-phenyl)-1-(p-hydroxyphenyl)-2-phenyl-but-1-ene
DE3047142C2 (en) Basic 1,7,7-trimethylbicyclo [2,2,1] heptyl ethers, process for the preparation thereof and medicaments containing them
US4584404A (en) Substituted phenoxyphenylproply dimethylamines
EP0002097A1 (en) Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
EP0024382A1 (en) Piperidine derivatives, their preparation and pharmaceutical compositions containing them
JPS6253504B2 (en)
US5646303A (en) Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein
US3205136A (en) Antidepressant phenyloxyalkylamines
US3862321A (en) Acyl xylidide local anaesthetics
US2918407A (en) Anti-spasmodics specific for upper gastrointestinal pain and spasm
US2957873A (en) Aralkylhydrazinium salts
US3078307A (en) Trifluoromethylphenylalkylamine derivatives
US3211792A (en) 1-(phenyl)-or 1-(alkyl-substitutedphenyl)-5-(substituted-phenyl)-3-aza penta-(1)-ols and salts thereof
US2497394A (en) Alkylaminoalkyl benzoates
US3180867A (en) Piperazine derivatives
US4259334A (en) Piperazines and therapeutic utility
US4271161A (en) Indane-acetic acid aminoesters, their preparation and their use in therapy
US4161532A (en) N-(1'-ethyl-2'-oxo-5'-pyrrolidinylmethyl) benzamide compounds and derivatives, method of preparation and pharmaceutical preparations
US2996507A (en) Piperazine compounds
US2750390A (en) Nicotinic acid ester
US4309544A (en) Preparation of 6-oxa-1-azatricyclo(6.2.2.02,7)dodecane-5-ones